CX-072 in patients with advanced/recurrent solid tumours or lymphomas
Research type
Research Study
Full title
An open-label, dose-finding and proof of concept study of the PD-L1 probody therapeutic, CX-072, as monotherapy and in combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in subjects with advanced or recurrent solid tumours or lymphomas
IRAS ID
211188
Contact name
Hendrik-Tobias Arkenau
Contact email
Sponsor organisation
CytomX Therapeutics, Inc
Eudract number
2016-002490-36
Clinicaltrials.gov Identifier
128042, IND Number
Duration of Study in the UK
2 years, 3 months, 13 days
Research summary
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue and organs. There are more than 200 types of cancer, including breast, lung, prostate, and lymphoma (cancer of the lymphatic system). Symptoms vary depending on the type. More than 1 in 3 people will develop some form of cancer during their lifetime.
Surgery is the first treatment for most cancer, as solid tumours can usually be surgically removed. Other commonly used treatments are chemotherapy (powerful cancer-killing medication) or radiotherapy (high-energy X-rays). Immunotherapy has been used with some success, but is limited by side effects. There is unmet need for drugs that limit immune activation to the tumour to enable new or more effective combination therapies.
CytomX Therapeutics, Inc. have developed a new drug, CX-072, that has been designed to act on the immune system protein PD-L1 at the tumour, but not in the rest of the body.
This study is being done to evaluate the safety and tolerability of CX-072 when given alone or in combination with ipilimumab and vemurafenib (approved cancer therapies) in patients with metastatic or advanced unresectable solid tumours or lymphomas.
This is a multicentre study which will take place across Europe and United States. It is anticipated that approximately 149 patients will be enrolled worldwide. Patients will be assigned to 1 of 5 parts of the study depending on the type of cancer they have and the time they begin treatment. Patients may receive intravenous (infusion directly into a vein) CX-072 on its own, CX-072 with ipilimumab, or CX-072 with oral vemurafenib. Treatment will be given either once every 2 or 3 weeks depending on the drug. Different doses of CX-072 will be given depending on results found in earlier stages of the study.REC name
South Central - Oxford B Research Ethics Committee
REC reference
17/SC/0109
Date of REC Opinion
30 May 2017
REC opinion
Further Information Favourable Opinion